F
Felipe A. Calvo
Researcher at University of Navarra
Publications - 225
Citations - 5054
Felipe A. Calvo is an academic researcher from University of Navarra. The author has contributed to research in topics: Radiation therapy & Intraoperative radiation therapy. The author has an hindex of 29, co-authored 219 publications receiving 4346 citations. Previous affiliations of Felipe A. Calvo include Complutense University of Madrid & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas,Patty J. Nelemans,Vincenzo Valentini,Prajnan Das,Claus Rödel,Li Jen Kuo,Felipe A. Calvo,Julio Garcia-Aguilar,Rob Glynne-Jones,Karin Haustermans,Mohammed Mohiuddin,Salvatore Pucciarelli,William Small,Javier Suárez,George Theodoropoulos,Sebastiano Biondo,Sebastiano Biondo,Regina G. H. Beets-Tan,Geerard L. Beets +18 more
TL;DR: Patients with pCR after chemoradiation have better long-term outcome than do those without pCR, and pCR might be indicative of a prognostically favourable biological tumour profile with less propensity for local or distant recurrence and improved survival.
Journal ArticleDOI
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial
Almudena Zapatero,A. Guerrero,Xavier Maldonado,Ana Alvarez,Carmen González San Segundo,Maria Angeles Cabeza Rodriguez,Víctor Macías,Agustí Pedro Olive,Francesc Casas,Ana Boladeras,Carmen Martín de Vidales,Maria Luisa Vazquez de la Torre,Salvador Villà,Aitor Perez de la Haza,Felipe A. Calvo +14 more
TL;DR: 5-year biochemical disease-free survival was significantly better among patients receiving long-term androgen deprivation than among those receiving short-term treatment, and 2 years of adjuvant androgens deprivation combined with high-dose radiotherapy improved biochemical control and overall survival in patients with prostate cancer.
Journal ArticleDOI
18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation
Felipe A. Calvo,Marta Domper,Raúl Matute,Raul Martinez-Lazaro,J.A. Arranz,Manuel Desco,Emilio Alvarez,José Luis Carreras +7 more
TL;DR: Preliminary results observed suggest the potential utility of FDG-PET as a complementary diagnostic procedure in the initial clinical evaluation as well as in the assessment of chemoradiation response (any T downstaged event) of locally advanced rectal cancer.
Journal ArticleDOI
Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients
Monique Maas,Patty J. Nelemans,Vincenzo Valentini,Christopher H. Crane,Carlo Capirci,Claus Rödel,Garrett M. Nash,Li Jen Kuo,Rob Glynne-Jones,Julio Garcia-Aguilar,Javier Suárez,Felipe A. Calvo,Salvatore Pucciarelli,Sebastiano Biondo,George Theodoropoulos,Doenja M. J. Lambregts,Regina G. H. Beets-Tan,Geerard L. Beets +17 more
TL;DR: In this article, the effect of adjuvant chemotherapy (aCT) for rectal cancer patients was evaluated by means of a pooled analysis of individual patient data from 13 datasets, where patients were categorized into three groups: pCR (ypT0N0), ypT1-2 tumour and YpT3-4 tumour.
Journal ArticleDOI
Intraoperative radiation therapy first part: rationale and techniques.
TL;DR: Criteria for patient's selection and evaluation and information on sequencing and techniques are presented as well as some considerations on the need for a proper programme on quality assurance and periodical reporting of data.